Melanoma biology and new targeted therapy (original) (raw)

• Slominski, A., Tobin, D. J., Shibahara, S. & Wortsman, J. Melanin pigmentation in mammalian skin and its hormonal regulation. Physiol. Rev. 84, 1155–1228 (2004).
  Article CAS PubMed Google Scholar
• Boissy, R. E. & Nordlund, J. J. Molecular basis of congenital hypopigmentary disorders in humans: a review. Pigment Cell Res. 10, 12–24 (1997).
  Article CAS PubMed Google Scholar
• Cummins, D. L. et al. Cutaneous malignant melanoma. Mayo Clin. Proc. 81, 500–507 (2006).
  Article PubMed Google Scholar
• Haass, N. K., Smalley, K. S. & Herlyn, M. The role of altered cell–cell communication in melanoma progression. J. Mol. Histol. 35, 309–318 (2004).
  Article CAS PubMed Google Scholar
• Miller, A. J. & Mihm, M. C. Melanoma. N. Engl. J. Med. 355, 51–65 (2006).
  Article CAS PubMed Google Scholar
• Clark, W. H. et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum. Pathol. 15, 1147–1165 (1984).
  Article PubMed Google Scholar
• Kuchelmeister, C., Schaumburg-Lever, G. & Garbe, C. Acral cutaneous melanoma in caucasians: clinical features, histopathology and prognosis in 112 patients. Br. J. Dermatol. 143, 275–280 (2000).
  Article CAS PubMed Google Scholar
• Ishihara, K., Saida, T. & Yamamoto, A. Updated statistical data for malignant melanoma in Japan. Int. J. Clin. Oncol. 6, 109–116 (2001).
  Article CAS PubMed Google Scholar
• Gilchrest, B. A., Eller, M. S., Geller, A. C. & Yaar, M. The pathogenesis of melanoma induced by ultraviolet radiation. N. Engl. J. Med. 340, 1341–1348 (1999).
  Article CAS PubMed Google Scholar
• Curtin, J. A. et al. Distinct sets of genetic alterations in melanoma. N. Engl. J. Med. 353, 2135–2147 (2005).
  Article CAS PubMed Google Scholar
• Wellbrock, C., Karasarides, M. & Marais, R. The RAF proteins take centre stage. Nature Rev. Mol. Cell Biol. 5, 875–885 (2004).
  Article CAS Google Scholar
• Bohm, M. et al. Identification of p90RSK as the probable CREB-Ser133 kinase in human melanocytes. Cell Growth Differ. 6, 291–302 (1995).
  CAS PubMed Google Scholar
• Wellbrock, C., Weisser, C., Geissinger, E., Troppmair, J. & Schartl, M. Activation of p59Fyn leads to melanocyte dedifferentiation by influencing MKP-1-regulated mitogen-activated protein kinase signaling. J. Biol. Chem. 277, 6443–6454 (2002).
  Article CAS PubMed Google Scholar
• Cohen, C. et al. Mitogen-actived protein kinase activation is an early event in melanoma progression. Clin. Cancer Res. 8, 3728–3733 (2002).
  CAS PubMed Google Scholar
• Satyamoorthy, K. et al. Constitutive mitogen-activated protein kinase activation in melanoma is mediated by both BRAF mutations and autocrine growth factor stimulation. Cancer Res. 63, 756–759 (2003).
  CAS PubMed Google Scholar
• Willmore-Payne, C., Holden, J. A., Tripp, S. & Layfield, L. J. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Hum. Pathol. 36, 486–493 (2005).
  Article CAS PubMed Google Scholar
• Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949–954 (2002).
  Article ADS CAS PubMed Google Scholar
• Ackermann, J. et al. Metastasizing melanoma formation caused by expression of activated N-RasQ61K on an INK4a-deficient background. Cancer Res. 65, 4005–4011 (2005).
  Article CAS PubMed Google Scholar
• Chin, L. et al. Essential role for oncogenic Ras in tumour maintenance. Nature 400, 468–472 (1999).
  Article ADS CAS PubMed Google Scholar
• Gray-Schopfer, V. C., da Rocha Dias, S. & Marais, R. The role of B-RAF in melanoma. Cancer Metastasis Rev. 24, 165–183 (2005).
  Article CAS PubMed Google Scholar
• Sharma, A. et al. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res. 65, 2412–2421 (2005).
  Article CAS PubMed Google Scholar
• Wellbrock, C. & Marais, R. Elevated expression of MITF counteracts B-RAF-stimulated melanocyte and melanoma cell proliferation. J. Cell Biol. 170, 703–708 (2005).
  Article CAS PubMed PubMed Central Google Scholar
• Goodall, J. et al. The Brn-2 transcription factor links activated BRAF to melanoma proliferation. Mol. Cell Biol. 24, 2923–2931 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Bhatt, K. V. et al. Adhesion control of cyclin D1 and p27Kip1 levels is deregulated in melanoma cells through BRAF–MEK–ERK signaling. Oncogene 24, 3459–3471 (2005).
  Article CAS PubMed Google Scholar
• Gray-Schopfer, V. C. et al. Cellular senescence in naevi and immortalisation in melanoma: a role for p16? Br. J. Cancer 95, 496–505 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Michaloglou, C. et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436, 720–724 (2005).
  Article ADS CAS PubMed Google Scholar
• Huntington, J. T. et al. Overexpression of collagenase 1 (MMP-1) is mediated by the ERK pathway in invasive melanoma cells: role of BRAF mutation and fibroblast growth factor signaling. J. Biol. Chem. 279, 33168–33176 (2004).
  Article CAS PubMed Google Scholar
• Ellerhorst, J. A. et al. Regulation of iNOS by the p44/42 mitogen-activated protein kinase pathway in human melanoma. Oncogene 25, 3956–3962 (2006).
  Article CAS PubMed Google Scholar
• Shaw, R. J. & Cantley, L. C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 441, 424–430 (2006).
  Article ADS CAS PubMed Google Scholar
• Omholt, K., Krockel, D., Ringborg, U. & Hansson, J. Mutations of PIK3CA are rare in cutaneous melanoma. Melanoma Res. 16, 197–200 (2006).
  Article CAS PubMed Google Scholar
• Wu, H., Goel, V. & Haluska, F. G. PTEN signaling pathways in melanoma. Oncogene 22, 3113–3122 (2003).
  Article CAS PubMed Google Scholar
• Stahl, J. M. et al. Deregulated Akt3 activity promotes development of malignant melanoma. Cancer Res. 64, 7002–7010 (2004).
  Article CAS PubMed Google Scholar
• Smalley, K. S. et al. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol. Cancer Ther. 5, 1136–1144 (2006).
  Article ADS CAS PubMed Google Scholar
• Tsao, H., Goel, V., Wu, H., Yang, G. & Haluska, F. G. Genetic interaction between NRAS and BRAF mutations and PTEN/MMAC1 inactivation in melanoma. J. Invest. Dermatol. 122, 337–341 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Wellbrock, C. et al. V599EB-RAF is an oncogene in melanocytes. Cancer Res. 64, 2338–2342 (2004).
  Article CAS PubMed Google Scholar
• Levy, C., Khaled, M. & Fisher, D. E. MITF: master regulator of melanocyte development and melanoma oncogene. Trends Mol. Med. 12, 406–414 (2006).
  Article CAS PubMed Google Scholar
• Selzer, E. et al. The melanocyte-specific isoform of the microphthalmia transcription factor affects the phenotype of human melanoma. Cancer Res. 62, 2098–2103 (2002).
  CAS PubMed Google Scholar
• Garraway, L. A. et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436, 117–122 (2005).
  Article ADS CAS PubMed Google Scholar
• Wu, M. et al. c-Kit triggers dual phosphorylations, which couple activation and degradation of the essential melanocyte factor Mi. Genes Dev. 14, 301–312 (2000).
  Article CAS PubMed PubMed Central Google Scholar
• Takeda, K. et al. Induction of melanocyte-specific microphthalmia-associated transcription factor by Wnt-3a. J. Biol. Chem. 275, 14013–14016 (2000).
  Article CAS PubMed Google Scholar
• Omholt, K., Platz, A., Ringborg, U. & Hansson, J. Cytoplasmic and nuclear accumulation of β-catenin is rarely caused by CTNNB1 exon 3 mutations in cutaneous malignant melanoma. Int. J. Cancer 92, 839–842 (2001).
  Article CAS PubMed Google Scholar
• Rimm, D. L., Caca, K., Hu, G., Harrison, F. B. & Fearon, E. R. Frequent nuclear/cytoplasmic localization of β-catenin without exon 3 mutations in malignant melanoma. Am. J. Pathol. 154, 325–329 (1999).
  Article CAS PubMed PubMed Central Google Scholar
• Worm, J., Christensen, C., Gronbaek, K., Tulchinsky, E. & Guldberg, P. Genetic and epigenetic alterations of the APC gene in malignant melanoma. Oncogene 23, 5215–5226 (2004).
  Article CAS PubMed Google Scholar
• Chen, D. et al. SKI activates Wnt/β-catenin signaling in human melanoma. Cancer Res. 63, 6626–6634 (2003).
  CAS PubMed Google Scholar
• Soengas, M. S. et al. Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature 409, 207–211 (2001).
  Article ADS CAS PubMed Google Scholar
• Bennett, D. C. Human melanocyte senescence and melanoma susceptibility genes. Oncogene 22, 3063–3069 (2003).
  Article CAS PubMed Google Scholar
• Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. Cell 100, 57–70 (2000).
  Article CAS PubMed Google Scholar
• Serrano, M., Hannon, G. J. & Beach, D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366, 704–707 (1993).
  Article ADS CAS PubMed Google Scholar
• Hayward, N. K. Genetics of melanoma predisposition. Oncogene 22, 3053–3062 (2003).
  Article CAS PubMed Google Scholar
• Sharpless, E. & Chin, L. The INK4a/ARF locus and melanoma. Oncogene 22, 3092–3098 (2003).
  Article CAS PubMed Google Scholar
• Polsky, D., Young, A. Z., Busam, K. J. & Alani, R. M. The transcriptional repressor of p16/Ink4a, Id1, is up-regulated in early melanomas. Cancer Res. 61, 6008–6011 (2001).
  CAS PubMed Google Scholar
• Sauter, E. R. et al. Cyclin D1 is a candidate oncogene in cutaneous melanoma. Cancer Res. 62, 3200–3206 (2002).
  CAS PubMed Google Scholar
• Pollock, P. M. et al. High frequency of BRAF mutations in nevi. Nature Genet. 33, 19–20 (2003).
  Article CAS PubMed Google Scholar
• Papp, T. et al. Mutational analysis of N-ras, p53, CDKN2A (p16 INK4a), _p14_ARF, CDK4, and MC1R genes in human dysplastic melanocytic naevi. J. Med. Genet. 40, E14 (2003).
  Article CAS PubMed PubMed Central Google Scholar
• Narita, M. et al. Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113, 703–716 (2003).
  Article CAS PubMed Google Scholar
• Soengas, M. S. & Lowe, S. W. Apoptosis and melanoma chemoresistance. Oncogene 22, 3138–3151 (2003).
  Article CAS PubMed Google Scholar
• Tarhini, A. A. & Agarwala, S. S. Cutaneous melanoma: available therapy for metastatic disease. Dermatol. Ther. 19, 19–25 (2006).
  Article PubMed Google Scholar
• Kirkwood, J. M., Moschos, S. & Wang, W. Strategies for the development of more effective adjuvant therapy of melanoma: current and future explorations of antibodies, cytokines, vaccines, and combinations. Clin. Cancer Res. 12, 2331s–2336s (2006).
  Article CAS PubMed Google Scholar
• Morgan, R. A. et al. Cancer regression in patients after transfer of genetically engineered lymphocytes. Science 314, 126–129 (2006).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Smalley, K. S. & Eisen, T. G. Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells. Int. J. Cancer 105, 165–175 (2003).
  Article CAS PubMed Google Scholar
• Wilhelm, S. M. et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 64, 7099–7109 (2004).
  Article CAS PubMed Google Scholar
• Flaherty, K. T. Chemotherapy and targeted therapy combinations in advanced melanoma. Clin. Cancer Res. 12, 2366s–2370s (2006).
  Article CAS PubMed Google Scholar
• Eisen, T. et al. Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis. Br. J. Cancer 95, 581–586 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Gray-Schopfer, V., Karasarides, M., Hayward, R. & Marais, R. Tumor necrosis factor-α blocks apoptosis in melanoma cells when BRAF signaling is inhibited. Cancer Res. 67, 122–129 (2007).
  Article CAS PubMed Google Scholar
• Adnane, L., Trail, P. A., Taylor, I. & Wilhelm, S. M. Sorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol. 407, 597–612 (2005).
  Article CAS Google Scholar
• Garnett, M. J., Rana, S., Paterson, H., Barford, D. & Marais, R. Wild-type and mutant B-RAF activate C-RAF through distinct mechanisms involving heterodimerization. Mol. Cell 20, 963–969 (2005).
  Article CAS PubMed Google Scholar
• Dumaz, N. et al. In melanoma, RAS mutations are accompanied by switching signaling from BRAF to CRAF and disrupted cyclic AMP signaling. Cancer Res. 66, 9483–9491 (2006).
  Article CAS PubMed Google Scholar
• Collisson, E. A., De, A., Suzuki, H., Gambhir, S. S. & Kolodney, M. S. Treatment of metastatic melanoma with an orally available inhibitor of the Ras–Raf–MAPK cascade. Cancer Res. 63, 5669–5673 (2003).
  CAS PubMed Google Scholar
• Solit, D. B. et al. BRAF mutation predicts sensitivity to MEK inhibition. Nature 439, 358–362 (2006).
  ADS CAS PubMed Google Scholar
• Koo, H. M. et al. Apoptosis and melanogenesis in human melanoma cells induced by anthrax lethal factor inactivation of mitogen-activated protein kinase kinase. Proc. Natl Acad. Sci. USA 99, 3052–3057 (2002).
  Article ADS CAS PubMed PubMed Central Google Scholar
• Beinke, S., Robinson, M. J., Hugunin, M. & Ley, S. C. Lipopolysaccharide activation of the TPL-2/MEK/extracellular signal-regulated kinase mitogen-activated protein kinase cascade is regulated by IκB kinase-induced proteolysis of NF-κB1 p105. Mol. Cell. Biol. 24, 9658–9667 (2004).
  Article CAS PubMed PubMed Central Google Scholar
• Dancey, J. E. Therapeutic targets: MTOR and related pathways. Cancer Biol. Ther. 5, 1065–1073 (2006).
  Article CAS PubMed Google Scholar
• Bush, J. A. & Li, G. The role of Bcl-2 family members in the progression of cutaneous melanoma. Clin. Exp. Metastasis 20, 531–539 (2003).
  Article CAS PubMed Google Scholar
• Nishimura, E. K., Granter, S. R. & Fisher, D. E. Mechanisms of hair graying: incomplete melanocyte stem cell maintenance in the niche. Science 307, 720–724 (2005).
  Article ADS CAS PubMed Google Scholar
• Jansen, B. et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nature Med. 4, 232–234 (1998).
  Article CAS PubMed Google Scholar
• Bedikian, A. Y. et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J. Clin. Oncol. 24, 4738–4745 (2006).
  Article CAS PubMed Google Scholar
• Del Bufalo, D., Trisciuoglio, D., Scarsella, M., Zangemeister-Wittke, U. & Zupi, G. Treatment of melanoma cells with a bcl-2/bcl-xL antisense oligonucleotide induces antiangiogenic activity. Oncogene 22, 8441–8447 (2003).
  Article CAS PubMed Google Scholar
• Fry, D. W. et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. Mol. Cancer Ther. 3, 1427–1438 (2004).
  CAS PubMed Google Scholar
• Sharp, S. & Workman, P. Inhibitors of the HSP90 molecular chaperone: current status. Adv. Cancer Res. 95, 323–348 (2006).
  Article CAS PubMed Google Scholar
• da Rocha Dias, S. et al. Activated B-RAF is an Hsp90 client protein that is targeted by the anticancer drug 17-allylamino-17-demethoxygeldanamycin. Cancer Res. 65, 10686–10691 (2005).
  Article CAS PubMed Google Scholar
• Grbovic, O. M. et al. V600E B-Raf requires the Hsp90 chaperone for stability and is degraded in response to Hsp90 inhibitors. Proc. Natl Acad. Sci. USA 103, 57–62 (2006).
  Article ADS CAS PubMed Google Scholar
• Amiri, K. I., Horton, L. W., LaFleur, B. J., Sosman, J. A. & Richmond, A. Augmenting chemosensitivity of malignant melanoma tumors via proteasome inhibition: implication for bortezomib (VELCADE, PS-341) as a therapeutic agent for malignant melanoma. Cancer Res. 64, 4912–4918 (2004).
  Article CAS PubMed Google Scholar
• Burke, J. R. et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κ B-dependent transcription in mice. J. Biol. Chem. 278, 1450–1456 (2003).
  Article CAS PubMed Google Scholar
• Rofstad, E. K. & Halsor, E. F. Vascular endothelial growth factor, interleukin 8, platelet-derived endothelial cell growth factor, and basic fibroblast growth factor promote angiogenesis and metastasis in human melanoma xenografts. Cancer Res. 60, 4932–4938 (2000).
  CAS PubMed Google Scholar
• Tucker, G. C. Integrins: molecular targets in cancer therapy. Curr. Oncol. Rep. 8, 96–103 (2006).
  Article CAS PubMed Google Scholar
• Gutheil, J. C. et al. Targeted antiangiogenic therapy for cancer using Vitaxin: a humanized monoclonal antibody to the integrin ανβ3 . Clin. Cancer Res. 6, 3056–3061 (2000).
  CAS PubMed Google Scholar
• Gupta, P. B., Mani, S., Yang, J., Hartwell, K. & Weinberg, R. A. The evolving portrait of cancer metastasis. Cold Spring Harb. Symp. Quant. Biol. 70, 291–297 (2005).
  Article CAS PubMed Google Scholar
• Kim, M. et al. Comparative oncogenomics identifies NEDD9 as a melanoma metastasis gene. Cell 125, 1269–1281 (2006).
  Article CAS PubMed Google Scholar
• Straume, O. & Akslen, L. A. Alterations and prognostic significance of p16 and p53 protein expression in subgroups of cutaneous melanoma. Int. J. Cancer 74, 535–539 (1997).
  Article CAS PubMed Google Scholar
• Lee, P. et al. ARRY-142886, a potent and selective MEK inhibitor: III) Efficacy in murine xenograft models correlates with decreased ERK phosphorylation. Proc. Am. Assoc. Cancer Res. 45, 897 (2004).
  Google Scholar
• Lyssikatos, J. et al. ARRY-142886, a potent and selective MEK inhibitor: I) ATP-independent inhibition results in high enzymatic and cellular selectivity. Proc. Am. Assoc. Cancer Res. 45, 896-b (2004).
  Google Scholar
• Yeh, T., Wallace, E., Lyssikatos, J. & Winkler, J. ARRY-142886, a potent and selective MEK inhibitor: II) Potency against cellular MEK leads to inhibition of cellular proliferation and induction of apoptosis in cell lines with mutant Ras or B-Raf. Proc. Am. Assoc. Cancer Res. 45, 896-c–897-c (2004).
  Google Scholar
• Morabito, A., De Maio, E., Di Maio, M., Normanno, N. & Perrone, F. Tyrosine kinase inhibitors of vascular endothelial growth factor receptors in clinical trials: current status and future directions. Oncologist 11, 753–764 (2006).
  Article CAS PubMed Google Scholar
• Peterson, A. C. et al. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma. Clin. Cancer Res. 10, 4048–4054 (2004).
  Article CAS PubMed Google Scholar
• Margolin, K. et al. CCI-779 in metastatic melanoma: a phase II trial of the California Cancer Consortium. Cancer 104, 1045–1048 (2005).
  Article CAS PubMed Google Scholar
• O'Donnell, A. et al. A phase I study of the oral mTOR inhibitor RAD001 as monotherapy to identify the optimal biologically effective dose using toxicity, pharmacokinetic (PK), and pharmacodynamic (PD) endpoints in patients with solid tumors. Proc. Am. Soc. Clin. Oncol. 22, Abstr. 806 (2003).
• End, D. W. et al. Characterization of the antitumor effects of the selective farnesyl protein transferase inhibitor R115777 in vivo and in vitro. Cancer Res. 61, 131–137 (2001).
  CAS PubMed Google Scholar
• Markovic, S. N. et al. A phase II study of bortezomib in the treatment of metastatic malignant melanoma. Cancer 103, 2584–2589 (2005).
  Article CAS PubMed Google Scholar
• Yang, J., Amiri, K. I., Burke, J. R., Schmid, J. A. & Richmond, A. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor κB and mitochondria pathways. Clin. Cancer Res. 12, 950–960 (2006).
  Article CAS PubMed PubMed Central Google Scholar
• Yaguchi, S. et al. Antitumor activity of ZSTK474, a new phosphatidylinositol 3-kinase inhibitor. J. Natl Cancer Inst. 98, 545–556 (2006).
  Article CAS PubMed Google Scholar